Kamada (KMDA)
(Delayed Data from NSDQ)
$5.56 USD
+0.02 (0.36%)
Updated Aug 22, 2024 04:00 PM ET
After-Market: $5.60 +0.04 (0.72%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Kamada Ltd. [KMDA]
Reports for Purchase
Showing records 1 - 20 ( 38 total )
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Possible Acceleration of AAT Trial - Cytogam and Kedrab Driving Near-Term Growth; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Kedrab Distribution Agreement and IgG Portfolio Leading Near-Term Growth; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Approved IgG Portfolio and Kedrab Driving Near-Term Growth in 2023; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
AAT and IgG Programs Yield Multiple Routes For Growth; Reit Buy and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Drivers For 2023 Platform Growth, AATD Pivotal Advancement; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Hyperimmune IgG Portfolio-Driver For 2023 Growth; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Supply Agreement and IgG Portfolio Direct Near-Term Progress; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Hyperimmune IgG Portfolio and Supply Agreement to Drive 2022 Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Growth Catalysts Front and Center - Looking to 2022 Plasma Expansion
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Prospects for 2022 Growth-Acquired Immunoglobulins Portfolio and Commercial Expansion
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Specialty Plasma Diversification Positioned to Drive 2022 Platform Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Plasma-Derived Vertical Integration Complemented By Hyperimmune Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Strides Towards Plasma-Derived Integration; Strategic Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Strategic Opportunities Across Platform Amid Backdrop of Glassia Transition
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Strides Taken to Broaden Plasma-Derived Platform Growth; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Plasma-Derived Immunoglobulin Potential in COVID-19; and Strategic Paths With Glassia Transition
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Progress for Plasma-Derived Hyperimmune IgG COVID-19 Therapy, Complemented by AAT Development in 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Plasma-Derived IgG Therapy for COVID-19, Inhaled AAT Front and Center for 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kamada Ltd.
Industry: Medical - Biomedical and Genetics
Planned Transition of Glassia Manufacturing Complemented by Business Development and Inhaled AAT Program Advancement
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A